Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failureopen access

Authors
Park, Sang MinLee, Soo YounJung, Mi-HyangYoun, Jong-ChanKim, DaraeCho, Jae YeongCho, Dong-HyukHyun, JunhoCho, Hyun-JaiPark, Seong-MiChoi, Jin-OhChung, Wook-JinKang, Seok-MinYoo, Byung-Su
Issue Date
Jul-2023
Publisher
Korean Society of Heart Failure
Keywords
Comorbidity; Disease management; Guideline; Heart failure
Citation
International Journal of Heart Failure, v.5, no.3, pp 127 - 145
Pages
19
Journal Title
International Journal of Heart Failure
Volume
5
Number
3
Start Page
127
End Page
145
URI
https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90972
DOI
10.36628/ijhf.2023.0016
ISSN
2636-154X
2636-1558
Abstract
Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea. In patients with HF with hypertension and left ventricular hypertrophy, renin-angiotensin system inhibitors combined with calcium channel blockers and/or diuretics is an effective treatment regimen. Measurement of pulmonary vascular resistance via right heart catheterization is recommended for patients with HF considered suitable for implantation of mechanical circulatory support devices or as heart transplantation candidates. Coronary angiography remains the gold standard for the diagnosis and reperfusion in patients with HF and angina pectoris refractory to antianginal medications. In patients with HF and atrial fibrillation, long-term anticoagulants are recommended according to the CHA2DS2-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF. Copyright © 2023. Korean Society of Heart Failure.
Files in This Item
There are no files associated with this item.
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Chung, Wook Jin photo

Chung, Wook Jin
College of Medicine (Department of Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE